Richard B. Moss

Overview

Best Publications

• A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

  Bonnie W. Ramsey;Jane Davies;N. Gerard McElvaney;Elizabeth Tullis

  2384
  Citations

• Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria

  R. Agarwal;A Chakrabarti;A. Shah;D. Gupta

  934
  Citations

• Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

  Frank J. Accurso;Steven M. Rowe;J. P. Clancy;Michael P. Boyle

  897
  Citations

• Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis—State of the Art: Cystic Fibrosis Foundation Consensus Conference

  David A. Stevens;Richard B. Moss;Viswanath P. Kurup;Alan P. Knutsen

  871
  Citations

• Late Pulmonary Sequelae of Bronchopulmonary Dysplasia

  William H. Northway;Richard B. Moss;Kathryn B. Carlisle;Bruce R. Parker

  675
  Citations

• Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

  J. P. Clancy;Steven M. Rowe;Frank J. Accurso;Moira L. Aitken

  639
  Citations

• Fungi and allergic lower respiratory tract diseases

  Alan P. Knutsen;Robert K. Bush;Jeffrey G. Demain;David W. Denning

  616
  Citations

• Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

  Ronald L. Gibson;Julia Emerson;Sharon McNamara;Jane L. Burns

  394
  Citations

• Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

  Richard B. Moss;David Rodman;L. Terry Spencer;Moira L. Aitken

  376
  Citations

• High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.

  Rabindra Tirouvanziam;Carol K. Conrad;Teodoro Bottiglieri;Leonore A. Herzenberg

  333
  Citations

• Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

  Michael W Konstan;Edward F McKone;Richard B Moss;Gautham Marigowda

  320
  Citations

• A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.

  John A. Wagner;Ilynn B. Nepomuceno;Anna H. Messner;Mary Lynn Moran

  316
  Citations

• Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

  Richard B Moss;Carlos Milla;John Colombo;Frank Accurso

  314
  Citations

• Absence of the β subunit (cchb1) of the skeletal muscle dihydropyridine receptor alters expression of the α1 subunit and eliminates excitation-contraction coupling

  Ronald G. Gregg;Albee Messing;Caroline Strube;Maryline Beurg

  297
  Citations

• Erratum: Allergic bronchopulmonary aspergillosis in cystic fibrosis - State of the art: Cystic Fibrosis Foundation Consensus Conference (Clinical Infectious Diseases (2003) 37:Suppl. 3 (S225-64))

  D. A. Stevens;R. B. Moss;V. P. Kurup;A. P. Knutsen

  283
  Citations

• A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease

  M.L. Aitken;R.B. Moss;D.A. Waltz;M.E. Dovey

  279
  Citations

• Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus

  John A Wagner;Thomas Reynolds;Mary Lynn Moran;Richard B Moss

  272
  Citations

• Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

  Scott D. Sagel;Ronald L. Gibson;Julia Emerson;Sharon McNamara

  251
  Citations

• Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

  John A. Wagner;Anna H. Messner;Mary Lynn Moran;Richard Daifuku

  251
  Citations

• Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

  Richard B Moss;Patrick A Flume;J Stuart Elborn;Jon Cooke

  219
  Citations